Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenqing Yao

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
European Journal of Pharmacology|August 31, 2020
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseasesMaryanne Covington, Xin He, Monika Scuron, et al.
Plos One|November 16, 2013
Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast ChinaBaocheng Deng, Bo Zhou, Shujun Zhang, et al.
ACS Medicinal Chemistry Letters|January 19, 2023
Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)Alexander Sokolsky, Oleg Vechorkin, Joshua R Hummel, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2Minh H Nguyen, Onur Atasoylu, Liangxing Wu, et al.
European Journal of Pharmacology|December 14, 2011
INCB38579, a novel and potent histamine H₄ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functionsNiu Shin, Maryanne Covington, Di Bian, et al.
Frontiers in Oncology|January 11, 2021
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted ActivityJonathan Rios-Doria, Margaret Favata, Kerri Lasky, et al.
Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) InhibitorLiangxing Wu, Colin Zhang, Chunhong He, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
Leukemia|May 22, 2021
Thyroid MALT lymphoma: self-harm to gain potential T-cell helpFangtian Wu, Natsuko Watanabe, Maria-Myrsini Tzioni, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
European Journal of Pharmacology|August 31, 2020
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseasesMaryanne Covington, Xin He, Monika Scuron, et al.
Plos One|November 16, 2013
Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast ChinaBaocheng Deng, Bo Zhou, Shujun Zhang, et al.
ACS Medicinal Chemistry Letters|January 19, 2023
Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)Alexander Sokolsky, Oleg Vechorkin, Joshua R Hummel, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2Minh H Nguyen, Onur Atasoylu, Liangxing Wu, et al.
European Journal of Pharmacology|December 14, 2011
INCB38579, a novel and potent histamine H₄ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functionsNiu Shin, Maryanne Covington, Di Bian, et al.
Frontiers in Oncology|January 11, 2021
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted ActivityJonathan Rios-Doria, Margaret Favata, Kerri Lasky, et al.
Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) InhibitorLiangxing Wu, Colin Zhang, Chunhong He, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
Leukemia|May 22, 2021
Thyroid MALT lymphoma: self-harm to gain potential T-cell helpFangtian Wu, Natsuko Watanabe, Maria-Myrsini Tzioni, et al.
Pageof 11